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(5.574 exposed and 14.596 not-exposed) were submitted to residential registries. 
The vital status of 96,6% of the study subjects could be confirmed by information 
of the registries. 80,7% were still alive 15 years after the accident (81% exposed, 80% 
not-exposed). 24,6% had died from cancer, 40,9% from cardiovascular diseases and 
31,8% from other causes of death. No effects of the exposure on the vital status 
could be determined (Cox-Regression). In the pharmacoepidemiological case study 
evaluating long term safety of hormone replacement therapy, the survival status of 
2.485 participants was investigated in country-wide residential databases. The vital 
status of 90,8% these participants could be confirmed using the registry information. 
2.250 were still alive after 4-5 years of inclusion into the study, only 6 deaths were 
identified and for only 9% the status could not be determined. ConClusions: 
Official residential registries can be a valuable source for investigating the survival 
status and the causes of death of study subjects in pharmaco- and general epide-
miological studies.
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RecRuiting MyelofibRosis Patients foR clinical and HealtH outcoMe 
studies using Managed PHysician Panels in 5 eu countRies
Eichmann F.1, Potthoff P.1, Brown C.2, Cholmakow-Bodechtel C.1
1Kantar Health Germany, Munich, Germany, 2All Global, London, UK
objeCtives: Myelofibrosis (MF) is a chronic blood cancer with an estimated prev-
alence in the US population of 4-5 patients per 100.000 inhabitants. Among the 
sources to recruit MF patients for post-approval studies in a real life environment, 
oncological or cardiological sites are of primary importance. The objective of the 
present contribution is to assess the number of MF patients in these specialties 
and the willingness of the physicians to enroll MF patients for clinical and health 
outcomes studies. Methods: In 2011, a feasibility survey assessing the incidence 
of MF patients in the sites of 94 oncologists, 72 hematologists and 65 cardiologists in 
5 EU countries (UK, GER, FR, IT, ES) was run, using the All Global managed physician 
panel. The willingness of these specialist groups to participate in clinical and health 
outcomes studies and to recruit patients for these studies was estimated among 
335 oncologists/hematologists and 208 cardiologists. Results: 88% of the oncolo-
gists and 99% of the hematologists treat Myelofibrosis patients (88% oncologists; 
99% hematologists). Cardiologists are involved in MF treatment to a smaller degree 
(75%). In 25% of all practices, less than 10 patients are treated per year, in 36%, 11 
to 50 patients, and in 38%, more than 50. Approximately 90% of the oncologists/
hematologists and 88% of the cardiologists are experienced in clinical and health 
outcomes studies; 80% of the oncologists/hematologists and 60% of the cardiolo-
gists are willing to participate in future studies and 92% resp. 94% in this group 
are willing to enroll patients for clinical and health outcome studies, including 
management of informed consent and ethics procedures as required for the study 
type. ConClusions: Myelofibrosis patients can be successfully recruited for clini-
cal and health outcomes studies using managed panels. Oncologists/hematologists 
and cardiologists are experienced in these study types and willing to participate 
in future studies.
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can gastRic canceR Patients be successfully RecRuited foR clinical 
PHase iii/iV and HealtH outcoMe studies using Managed PHysician 
Panels?
Eichmann F.1, Potthoff P.2, Brown C.3
1Kantar Health, Munich, Germany, 2Kantar Health Germany, Munich, Germany, 3All Global, 
London, UK
objeCtives: Gastric cancer (GC) is a cancer arising from parts of the stomach. To 
recruit GC patients for post-approval studies in a real world environment, oncologi-
cal, hematological, and internist sites might be of primary importance. The present 
contribution assesses the number of GC patients in these sites and the willingness 
of physicians to enroll GC patients for health outcome or clinical phase III/IV studies. 
Methods: In 2011 a feasibility study about the number of GC patients was run 
in the sites of 63 oncologists, 23 hemato-oncologists and 26 internists in UK (16), 
GER (19), FR (11), IT (27), ES (27), and US (12). Physicians reported about the number 
of “new patients with unresectable, locally advanced or metastatic gastric or gas-
troesophageal junction (GEJ) adenocarcinoma”. The willingness of these specialist 
groups to participate in clinical phase III/IV or health outcome studies was also 
estimated in a different survey. Results: In total these 112 specialists have seen 
approximately 3,200 new gastric cancer patients in the last 6 months. In average 
(median values) oncologists have seen 30 new gastric cancer patients in 6 months, 
hematologists 20 patients and internists 6 patients. Most of the patients (2,600) have 
been treated with chemotherapy. Approximately 90% of the oncologists/hematolo-
gists and 88% of the cardiologists are experienced in clinical phase III/IV or health 
outcome studies; 80% of the oncologists/hematologists and 60% of the cardiologists 
are willing to participate in future studies and 92% resp. 94% in this group are willing 
to enroll patients for clinical phase III/IV or health outcome studies and ask them for 
written informed consent. ConClusions: Patients suffering from Gastric Cancer 
can be successfully recruited for clinical phase III/IV or health outcome studies 
using managed panels. Oncologists/hematologists and cardiologists are usually 
experienced in these studies.
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assessing tHe RelationsHiP between tReatMent effect and baseline 
Risk in netwoRk Meta-analsysis of ModeRate to seVeRe cHRonic 
Plaque PsoRiasis tRials
Smiechowski B.1, Cope S.2
1Mapi, Boston, MA, USA, 2Mapi, Toronto, ON, Canada
objeCtives: To investigate differences across randomized controlled trials (RCTs) 
evaluating biological therapies for the treatment of moderate to severe chronic 
plaque psoriasis in terms of baseline risk in psoriasis area severity index score (PASI) 
and the association with treatment effects by means of network meta-analysis 
(NMA). Methods: 25 RCTs reporting the proportion of patients experiencing a 
0.2). However, absolute risk reduction was generally higher in high risk strata, 
ranging from -1.4 to 18.3% (median= 4.6%; IQR= 0.8-6.1%) in quartile one and from 
0.8 to 35.0% (median= 11.5%; IQR= 3.3-19.8%) in quartile four. The difference in 
the absolute risk reduction between the extreme risk quartile ranged from -3.2 to 
28.3% (median= 7.7%; IQR= 0.3-11.3). ConClusions: Clinically significant HTE is 
common even in phase 3 “efficacy” trials on the absolute scale. A multivariate risk 
stratified approach to subgroup analysis is feasible and often clinically informative 
when assessing treatment efficacy.
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non-tReatMent sPecific PaRaMeteR Value estiMates: RelationsHiP 
between bMi and utility
Halfpenny N.J.A.1, Quigley J.M.1, Donatti C.2, Hawkins N.S.1
1ICON Health Economics, Oxford, UK, 2Janssen-Cilag UK, High Wycombe, UK
objeCtives: Cost-effectiveness models are an important component of health 
economic evaluation. In addition to estimates of treatment effects (typically 
estimated for RCTs), cost-effectiveness estimates may be sensitive to estimates of 
non-treatment specific parameters that describe the relationship between model 
variables. These may be estimated from epidemiological studies that themselves 
include covariable adjustment in order to account for potential confounding. We use 
the example of the estimated relationship between BMI and utility as to illustrate 
methods for the review meta-analysis of parameter estimates arising from multi-
ple studies and issues around the selection of appropriate estimates. Methods: 
A targeted search was carried out in MEDLINE and EMBASE for studies with utility 
data on BMI. The outcome was utility change per unit increase in BMI. Study charac-
teristics recorded included the utility instrument used, study location, diabetes sta-
tus and number of covariates. Fixed and random effects models as well as graphical 
methods were used to investigate the influence of study characteristics. Results: 
Several utility scales were used throughout with some using multiple utility scales 
within the study to assess quality of life. EQ5-D and SF-6D were the most com-
monly used utility scales. Using a random effects model we observed a change 
in utility per unit increase in BMI of -0.0054 [-0.0077; -0.0031]. However there was 
significant heterogeneity between studies. The number of covariates ranged greatly 
between the studies and appeared predictive of the magnitude of effect of BMI on 
utility. ConClusions: We illustrate methods for meta-analysing multiple param-
eter estimates and discuss the selection of appropriate parameter estimates for the 
inclusion in cost-effectiveness models. In particular we illustrate the relationship 
between the selection of appropriate parameter estimates in terms of which covari-
ables were included in the originating studies and the cost-effectiveness model 
structure in terms of which independent causal effects are modelled.
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Schuchardt M.1, Khoury C.2, Friedmann B.3, Haigh J.4
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objeCtives: This research was conducted to understand key reasons why the G-BA 
came to a different benefit rating than IQWiG during oncology HTAs. Methods: 
Searching the G-BA and IQWiG homepages, oncology HTAs between 1st of January 
2011 and 31st of December 2013 have been identified. Assessments for which the 
G-BA attested a benefit rating divergent from the one proposed by IQWiG have been 
analyzed to reveal the key reasons for difference. Results: In the observed time 
frame, 18 HTAs of oncology products have been conducted by IQWiG and G-BA in 
Germany. IQWiG and G-BA were aligned in their benefit ratings in 14 reports (78%). 
During four assessments (22%) the G-BA came to a different conclusion than IQWiG. 
These are the assessments of crizotinib, eribulin, pertuzumab and the resubmission 
for vandentanib. One reason for different ratings observed in three assessments 
is that the G-BA looked at time-adjusted analyses to correct for different lengths 
of treatment in the trial arms. The extend of benefit that is extracted from the 
same data also potentially differs. This is exemplified by the case of vandentanib, 
where the G-BA was more convinced by the data on “time to worsening of pain” 
than IQWiG and attested a “minor benefit” (as compared to “no added benefit”). 
In the case of eribulin, G-BA and IQWiG agreed on benefit based on survival data. 
Due to the potential side effects however, G-BA demoted to “minor”, while IQWiG 
initially demoted to “no added benefit”. ConClusions: The translation of clinical 
evidence into a benefit rating and weighing of positive versus negative effects is 
highly complex. We see that G-BA and IQWiG can come to different conclusions. In 
all cases it is important that the manufacturer shows evidence against the speci-
fied comparator. The benefit rating plays an important role in the reimbursement 
amount negotiations.
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suRViVal status in (PHaRMaco) ePideMiological studies can be 
successfully inVestigated using adMinistRatiVe Residential 
RegistRies
Potthoff P., Eichmann F., Klamert A.
Kantar Health Germany, Munich, Germany
objeCtives: Study subject survival is a key outcome and endpoint in pharmacoepi-
demiological studies. When participants in long-term studies drop out, administra-
tive residential registries can be a useful source to investigate subjects’ vital status. 
The present contribution reports procedures and results of vital status inquiries 
in German administrative residential databases. A pharmacoepidemiological and 
an environmental exposure study are used as case studies. Methods: For both 
case studies, residential addresses of study participants were submitted to the 
responsible official residential register with the purpose of collecting information 
about vital status or – in case of address changes – the new address was collected. 
For persons with multiple address changes up to 7 inquiry loops were necessary 
until vital status could be ascertained. Results: In the environmental case study 
assessing effects of an urban chemical accident, 20.170 addresses of German citizens 
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objeCtives: Traditional Medicine and the use of herbal interventions are regarded 
as an integral part of health care among countries of Association of Southeast Asian 
Nations (ASEAN). To date numerous randomised controlled trials (RCTs) of herbal 
interventions have been conducted within ASEAN. It is recognised that good qual-
ity reporting of RCTs is crucial to the assessment of clinical significance. ASEAN 
has placed strong emphasis on the facilitation of research in Traditional Medicine, 
especially in the strengthening of evidence base for herbal medicines. The objective 
of this study was to systematically review the quality of reporting of RCTs of herbal 
interventions conducted in ASEAN Plus Six Countries. Methods: Searches were 
performed using PubMed, EMBASE and MEDLINE, The Cochrane Library, and Allied 
and Complementary Medicine (AMED), from inception through October 2013. The 
following limits were applied: Human; RCTs. Herbal species search terms were 
based on those listed in the National List of Essential Medicines [NLEM (Thailand, 
2011)]. Studies conducted in ASEAN Plus Six Countries, published in English were 
included. Quality of reporting was assessed according to the 22-item Elaborated 
CONSORT statement for reporting RCTs of herbal interventions. Results: Seventy-
one articles were identified, of which thirty RCTs (42.25%) were conducted in ASEAN 
Countries, whereas 41 RCTs (57.75%) were from the Plus Six Group. Adherence to 
the recommended CONSORT checklist items for reporting of RCTs of herbal inter-
ventions among ASEAN Plus Six Countries ranged from 0% to 97.18%. Less than 
half of the RCTs reported methods used to generate random sequence allocation 
(item 8,47.89%), and implement random allocation sequence (item 9 allocation con-
cealment, 29.58%). Less than a quarter of RCTs (18.31%) reported information on 
standardisation of herbal products. ConClusions: The present study highlighted 
the need to improve reporting quality of RCTs of herbal interventions across ASEAN 
Plus Six Communities.
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endPoints in Pain: tHe suitability foR HealtH econoMic eValuation 
of endPoint designs in cHRonic Pain studies
Rycroft C.1, Hirst M.2, Dunlop W.2, Pirk O.3, Mullins C.D.4, Akehurst R.5
1BresMed, Sheffield, UK, 2Mundipharma International Limited, Cambridge, UK, 3Olaf Pirk 
Consult, Nürnberg, Germany, 4University of Maryland School of Pharmacy, Baltimore, MD, USA, 
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objeCtives: A wide range of instruments are used to measure outcomes in clinical 
studies of chronic pain. However, the suitability of study outcomes for economic 
evaluations in chronic pain is limited by variability in the instruments used and 
the failure of those that are in common use to adequately capture the dimensions 
of a patient’s experience of pain, including function, quality of life and tolerability. 
The current study aims to identify the pain instruments and study endpoints most 
commonly used in the clinical trial setting. Methods: A structured, comprehensive 
literature review of ongoing registered trials (trial registries) and published clini-
cal studies (PubMed) in the areas of chronic pain (cancer, non-cancer and neuro-
pathic), pain in elderly patients, and breakthrough pain was conducted. Inclusion 
criteria were: interventional study, pain population of interest and pain measured 
within primary endpoint. Data were extracted from identified publications focus-
ing on primary and secondary endpoints reported, and primary pain instrument 
used. Results: Of 1,256 citations retrieved, 132 were included as they reported 
large clinical studies in pain populations. The majority of primary endpoints were 
pure pain measures (112), most commonly: numerical rating scale (NRS) (44), visual 
analogue scale (VAS) (34), and brief pain inventory (BPI) (18). Other outcome domains 
were typically limited to secondary endpoints and were not consistently applied 
across the studies. These include measures of function (47), quality of life (36), 
safety/tolerability (33), emotional wellbeing (26) and sleep (20). ConClusions: 
The majority of studies still use simple pain measures as their primary outcomes. 
Useful economic outcomes such as quality of life and function are relegated to 
secondary endpoints and are inconsistently used. Types of pain instruments cur-
rently used in registered, ongoing trials will also be reported. Further research is 
needed to consider which existing endpoint designs constitute best practise and 
if new designs are required.
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coMPaRatiVe Real woRld effectiVeness of noVel agents VeRsus 
conVentional tHeRaPies in MultiPle MyeloMa Patients in sweden
Thilakarathne P.1, Diels J.2, van Sanden S.3, Liwing J.4, Van Agthoven M.5, Chirita O.6, Nahi H.7
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Belgium, 3EMEA HEMAR Analytics, Janssen EMEA, Beerse, Belgium, 4Janssen-Cilag AB, 
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objeCtives: Comparing outcomes between different treatments based on real 
world evidence can be challenging, first because of confounding due to lack of ran-
domization at treatment initiation, and secondly due to selection bias induced by 
selective treatment switching. To account for both sources of bias, we explored the 
Inverse probability of censoring weights analysis (IPCW) to account for this bias on 
a retrospective dataset of multiple myeloma patients in Sweden. Methods: IPCW-
approach was used to additionally adjust for bias induced by selective treatment 
switching in 2 steps. First, time-varying weights were estimated using multivariate 
logistic regression, including age, gender, stage, M-protein type, creatinine-clearance 
as baseline covariates and M-protein as time-varying covariate. Secondly, these 
time-dependent weights were incorporated in a proportional hazards model, includ-
ing treatment and baseline characteristics, with patients censored at initiation of 
subsequent therapy. ITT-estimates were generated based on multivariate propor-
tional hazards model, including the same baseline covariates. Results: In the total 
MM population (n= 1638), the non-transplant population was 1125, of which 31% 
(n= 349) received novel therapies (bortezomib, lenalidomide and thalidomide based) 
while 69% had conventional therapies in frontline. Mean age was 71/75 respectively. 
The mean baseline serum m-protein level was 30.9 g/L for both groups. The ITT HR in 
frontline was 0.56 [0.45, 0.70] and IPCW-adjusted HR is 0.31 [0.22, 0.42]. ITT vs IPCW-
based HR for 2nd and 3rd line of therapy were 0.71 [0.58, 0.87] vs 0.667 [0.487, 0.914] 
75% improvement from baseline in PASI (PASI 75) at the end of the trial were identi-
fied from two recently published NMAs focused on the efficacy of biologics in the 
treatment of moderate to severe psoriasis based on a systematic literature review. 
Differences in baseline risk of PASI 75 were explored graphically. The association 
between the treatment effect of 19 different biologics and baseline risk of PASI 
75 with placebo was assessed by conducting a Bayesian NMA with baseline risk 
covariate adjustment using a model assuming a constant treatment by covariate 
interaction, and a normal distribution for baseline risk. The model also allowed for 
the baseline risk adjustment of RCTs that did not include a placebo arm. Results: 
Across the RCTs, PASI 75 at the end of the trial period for patients in the placebo arm 
ranged from 2% to 19%. The coefficient for baseline risk was a median of -0.33 (95% 
credible intervals: -0.79, 0.21) which suggested baseline risk was not significantly 
associated with the proportion achieving PASI 75 across the RCTs. ConClusions: 
Based on a NMA of RCTs regarding the efficacy of biologics in terms of PASI 75, it 
is unclear if baseline risk of PASI 75 acts as a treatment effect modifier. Further 
analyses are required to assess whether baseline risk may explain differences in 
the classes of biological therapies used to treatment moderate to severe psoriasis.
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Riding tHe e-Publication waVe
Quigley J.M., Thompson J.C., Halfpenny N., Scott D.A., Hawkins N.S.
ICON Health Economics, Oxford, UK
objeCtives: Submissions to Health Technology Assessment (HTA) bodies must 
include the most up-to-date information on comparator technologies. This ena-
bles HTA bodies to make fully informed decisions. In order to ensure up-to-date 
information is obtained, all relevant data sources should be searched. At present 
HTA method guidelines generally specify that a core set of databases comprising 
EMBASE, MEDLINE, MEDLINE-in-process and the Cochrane Library are searched. 
However, in an attempt to manage the increasing quantity of research, journals 
are publishing more articles ahead of print as online e-publications. E-publications 
ahead of print are identifiable in PubMed but are not indexed in EMBASE, MEDLINE 
or Cochrane. Methods: We selected a NICE guideline published in June 2014 for 
ablation techniques in atrial fibrillation which searched for randomised clini-
cal trials (RCT) in the common databases. We updated the searches in EMBASE, 
MEDLINE, MEDLINE-in-process and the Cochrane Library from the date of the last 
search, to identify any studies published since the guideline was published. We 
concurrently searched PubMed using a filter to identify studies only available as 
e-publications ahead of print. Results: We identified one RCT meeting the inclu-
sion criteria that was retrieved by the search in PubMed but was not identified by 
searching in EMBASE, MEDLINE or Cochrane (all searches being run on the same 
date). ConClusions: If studies are missed from systematic reviews there can be 
important implications on clinical efficacy comparisons. To produce the most up-
to-date systematic review, with all available full papers it is necessary to search 
for e-publications ahead of print in PubMed as well as for all other publications in 
EMBASE, MEDLINE and Cochrane.
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indiVidualised gRowtH ResPonse oPtiMisation (igRo): a Multi-
language softwaRe Medical deVice to PRedict gRowtH ResPonse in 
cHildRen tReated witH gRowtH HoRMone (gH)
Loftus J.1, Lindberg A.2, Aydin F.2, Rawlings F.3, Ranke M.4, Camacho-Hubner C.5
1Pfizer Ltd, Tadworth, UK, 2Pfizer, Sollentuna, Sweden, 3Pfizer Inc, Collegeville, PA, USA, 
4University Children’s Hospital, Tuebingen, Germany, 5Pfizer Inc, New York, NY, USA
objeCtives: To produce a modern, accessible, quick and intuitive growth prediction 
tool in which growth prediction models (GPMs) were clinically validated. Methods: 
GPMs support physicians to optimise and monitor GH treatment and response. They 
are validated, providing accurate predictions of growth response following GH treat-
ment in children with idiopathic growth hormone deficiency (IGHD), Turner syn-
drome (TS) and short children born small for gestational age (SGA). By using GPMs, 
realistic expectations of treatment outcomes are conveyed to patients and parents 
(important as children respond differently to treatment). A modern platform, a 
website, will host iGRO; the software should ensure web browser compatibility in 
European endocrine clinics. An internal paediatric endocrinologist robustly tested 
the GPMs. User acceptance testing (UAT) for acceptability and usability was con-
ducted with external paediatric endocrinologists. These outputs contribute to the 
Class I medical device Technical File; a requirement for iGRO. Results: The clinical 
validation performed under simulated conditions using the final medical device 
software passed, consistent with regulatory expectations. GPMs for IGHD, SGA, TS 
were tested for prediction accuracy. Validation acceptance criteria and test results 
were included in the test script records. UAT was designed and executed following 
a rigorous software development lifecycle methodology to ensure completeness 
of the tool and the specified business and user requirements. UAT was certified 
through role based testing scenarios (requirements and processes for daily use). The 
tool, accessed via a secure password protected website, was easily navigated and 
provided a clear interface requiring little training. Data entry was quick and growth 
outcomes (i.e. graphical comparisons between patient’s actual growth response and 
one-year predictions) were easily viewed. ConClusions: iGRO, an accessible web-
based software medical device, provides accurate growth prediction which enable 
physicians to monitor patients’ response to GH treatment. It may potentially be 
used to detect discrepancies early.
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